SANARA MEDTECH INC (SMTI) Stock Price, Forecast & Analysis

NASDAQ:SMTI • US79957L1008

20.45 USD
+0.51 (+2.56%)
Last: Feb 20, 2026, 08:05 PM

SMTI Key Statistics, Chart & Performance

Key Statistics
Market Cap182.82M
Revenue(TTM)101.90M
Net Income(TTM)-37.49M
Shares8.94M
Float2.34M
52 Week High36.31
52 Week Low18.29
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.73
PEN/A
Fwd PE16.23
Earnings (Next)03-23
IPO1994-04-07
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
SMTI short term performance overview.The bars show the price performance of SMTI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

SMTI long term performance overview.The bars show the price performance of SMTI in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of SMTI is 20.45 USD. In the past month the price decreased by -8.09%. In the past year, price decreased by -39.3%.

SANARA MEDTECH INC / SMTI Daily stock chart

SMTI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
SMTI Full Technical Analysis Report

SMTI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SMTI. SMTI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SMTI Full Fundamental Analysis Report

SMTI Financial Highlights

Over the last trailing twelve months SMTI reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 26.06% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -52.74%
ROE -609.72%
Debt/Equity 7.33
Chartmill High Growth Momentum
EPS Q2Q%126.47%
Sales Q2Q%21.51%
EPS 1Y (TTM)26.06%
Revenue 1Y (TTM)30.55%
SMTI financials

SMTI Forecast & Estimates

8 analysts have analysed SMTI and the average price target is 40.8 USD. This implies a price increase of 99.51% is expected in the next year compared to the current price of 20.45.

For the next year, analysts expect an EPS growth of 117% and a revenue growth 18.97% for SMTI


Analysts
Analysts82.5
Price Target40.8 (99.51%)
EPS Next Y117%
Revenue Next Year18.97%
SMTI Analyst EstimatesSMTI Analyst Ratings

SMTI Ownership

Ownership
Inst Owners12.84%
Ins Owners8.75%
Short Float %9.04%
Short Ratio3.88
SMTI Ownership

SMTI Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
MDLN MEDLINE INC-CL A33.365.423B
COO COOPER COS INC/THE18.4316.476B
ALGN ALIGN TECHNOLOGY INC16.9613.634B
SOLV SOLVENTUM CORP11.2712.651B
LNTH LANTHEUS HOLDINGS INC13.074.898B
MMSI MERIT MEDICAL SYSTEMS INC19.924.874B
ICUI ICU MEDICAL INC19.143.877B
HAE HAEMONETICS CORP/MASS11.152.844B
XRAY DENTSPLY SIRONA INC8.052.502B
NEOG NEOGEN CORP33.412.465B

About SMTI

Company Profile

SMTI logo image Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

Company Info

SANARA MEDTECH INC

1200 Summit Avenue, Suite 414

Fort Worth TEXAS 76102 US

CEO: Ronald T. Nixon

Employees: 141

SMTI Company Website

SMTI Investor Relations

Phone: 18175292300

SANARA MEDTECH INC / SMTI FAQ

What does SMTI do?

Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.


Can you provide the latest stock price for SANARA MEDTECH INC?

The current stock price of SMTI is 20.45 USD. The price increased by 2.56% in the last trading session.


Does SMTI stock pay dividends?

SMTI does not pay a dividend.


How is the ChartMill rating for SANARA MEDTECH INC?

SMTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What sector and industry does SANARA MEDTECH INC belong to?

SANARA MEDTECH INC (SMTI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


What is SANARA MEDTECH INC worth?

SANARA MEDTECH INC (SMTI) has a market capitalization of 182.82M USD. This makes SMTI a Micro Cap stock.